Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C

Table 4 Diagnostic performance of five non-invasive tests for determining significant steatosis (> 33% of hepatocytes)

Significant steatosis (> 33% of hepatocytes)
Test	APRI	M-APRI	FIB-4	M-FIB-4	B-AST
AUROC (95% CI)	0.837 (0.657–0.945)	0.923 (0.820–0.999)	0.683 (0.488–0.840)	0.942 (0.792–0.994)	0.942 (0.792–0.994)
Cut-off	0.656	0.577	0.216	0.179	92.82
Sensitivity (95% CI)	75 (19.4–99.4)	100 (39.8–100)	75 (19.4–99.4)	100 (39.8–100)	100 (39.8–100)
Specificity (95% CI)	88.46 (69.8–97.6)	92.3 (74.9–99.1)	73.1 (52.2–88.4)	88.46 (69.8–97.6)	92.3 (74.9–99.1)
+ PV	50.0 (23.1–76.9)	66.7 (34.6–88.3)	30.0 (15.5–50.0)	57.1 (31.5–79.4)	66.7 (34.6–88.3)
- PV	95.8 (80.7–99.2)	100	95.0 (77.4–99.1)	100	100

APRI aspartate-to-platelet ratio index, FIB-4 Fibrosis-4 index, M-APRI modified aspartate-to-platelet ratio index (BMI z-score x APRI), M-FIB-4 modified Fibrosis-4 index (BMI z-score x FIB-4), B-AST BMI z-score x AST, AUROC area under the receiver operating characteristic, 95% CI 95% confidence interval, + PV positive predictive value, − PV negative predictive value

ISSN: 1471-2334